These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15851788)

  • 21. Bevacizumab in colorectal cancer.
    Sharieff W
    N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15490497
    [No Abstract]   [Full Text] [Related]  

  • 22. Methods of overcoming treatment resistance in colorectal cancer.
    Temraz S; Mukherji D; Alameddine R; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):217-30. PubMed ID: 24075059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perforating dermatosis in a patient receiving bevacizumab.
    Vano-Galvan S; Moreno C; Medina J; Pérez-García B; García-López JL; Jaén P
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
    [No Abstract]   [Full Text] [Related]  

  • 24. Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
    Normanno N; Tejpar S; Ciardiello F
    J Natl Cancer Inst; 2010 Apr; 102(8):573; author reply 573-5. PubMed ID: 20305131
    [No Abstract]   [Full Text] [Related]  

  • 25. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
    Maung K; Lee D; DeGrendele HC; Schilsky R; Chu E; Jain VK; Copur S
    Clin Colorectal Cancer; 2002 Nov; 2(3):140-5. PubMed ID: 12482329
    [No Abstract]   [Full Text] [Related]  

  • 26. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
    Jackson C; Cunningham D
    Eur J Cancer; 2008 Mar; 44(5):652-62. PubMed ID: 18313913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
    Pietrantonio F; Garassino MC; Torri V; de Braud F
    Ann Oncol; 2012 Oct; 23(10):2771-2772. PubMed ID: 22875835
    [No Abstract]   [Full Text] [Related]  

  • 28. [Chemotherapy for elderly patients with colorectal cancer].
    Kuboki Y; Mizunuma N
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):380-6. PubMed ID: 17353628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New therapy options in colorectal carcinoma].
    Folprecht G; Köhne CH
    Ther Umsch; 2004 Jun; 61(6):373-8. PubMed ID: 15253162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cetuximab after bevacizumab in metastatic colorectal cancer: is it the best sequence?
    Norguet E; Dahan L; Gaudart J; Gasmi M; Ouafik L; Seitz JF
    Dig Liver Dis; 2011 Nov; 43(11):917-9. PubMed ID: 21763224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
    Boisen MK; Johansen JS; Larsen O; Jensen BV
    Oncology; 2011; 80(1-2):138-9. PubMed ID: 21677460
    [No Abstract]   [Full Text] [Related]  

  • 32. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
    Li J
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
    [No Abstract]   [Full Text] [Related]  

  • 34. First description of an uterine perforation potentially imputable to treatment with bevacizumab.
    Uguen T; Leconte B; Desgrippes R; Tchoundeu B; Bretagne JF; Manfredi S
    Acta Oncol; 2012 Nov; 51(8):1102-4. PubMed ID: 23020310
    [No Abstract]   [Full Text] [Related]  

  • 35. Oncological management of unresectable liver metastases.
    Prenen H; Van Cutsem E
    Dig Dis; 2012; 30 Suppl 2():137-42. PubMed ID: 23207946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ERBITUX as a single agent and in combination in colorectal carcinoma.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):242. PubMed ID: 12113039
    [No Abstract]   [Full Text] [Related]  

  • 37. Cetuximab or bevacizumab in metastatic colorectal cancer?
    Sclafani F; Cunningham D
    Lancet Oncol; 2014 Sep; 15(10):1040-1. PubMed ID: 25088941
    [No Abstract]   [Full Text] [Related]  

  • 38. How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
    Lindsay CR; Roxburgh P; Graham J
    Future Oncol; 2013 Jun; 9(6):825-9. PubMed ID: 23718303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Palliative chemotherapy and radiotherapy for metastatic colorectal cancer].
    Sørbye H; Braendengen M; Balteskard L
    Tidsskr Nor Laegeforen; 2008 Jan; 128(2):194-7. PubMed ID: 18202732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
    Kabbinavar F; Kozloff M
    Oncology; 2011; 80(1-2):135-7; author reply 140-1. PubMed ID: 21677459
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.